BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Doxorubicin: trial readouts and FDA decisions

3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 7 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: InSightec, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Spirovant Sciences, Inc., Merck Sharp & Dohme LLC, Zhejiang Teruisi Pharmaceutical Inc., Incyte Corporation, Celgene, Actuate Therapeutics Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-30 est.P3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06751485 JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian CancerOvarian Cancer; Primary Peritoneal; Fallopian Tube Cancersnot yet recruiting430
2026-12-31 est.P1/P2Spirovant Sciences, Inc.NCT06526923 A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)Cystic Fibrosisrecruiting15
2027-02-12 est.P2Merck Sharp & Dohme LLC MRKNCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Hodgkin Lymphomaactive not recruiting340

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-01 est.P1/P2Zhejiang Teruisi Pharmaceutical Inc.NCT07035379 A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCLDiffuse Large B-Cell Lymphoma (DLBCL)not yet recruiting66
2026-09-01 est.P3Incyte Corporation INCYNCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsDiffuse Large B-cell Lymphomaactive not recruiting899
2026-06-19P2CelgeneNCT06425302 A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaLymphoma, Follicularactive not recruiting95
2026-06 est.P1/P2InSightecNCT05630209 Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)Brain Tumoractive not recruiting10
2026-06 est.P1/P2InSightecNCT05615623 Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPGBrain Tumoractive not recruiting10
2026-06 est.P2Actuate Therapeutics Inc. ACTUNCT03678883 9-ING-41 in Patients With Advanced CancersCancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractoryactive not recruiting350
2026-05-31 est.P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06394492 SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerOvarian Cancerrecruiting440

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.